Leishmaniasis
Drug research and approvals for leishmaniasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 17 studies of leishmaniasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 13 open orphan designations naming it.
- Recruiting worldwide: 17
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 0
- High-Frequency Ultrasound Monitoring of Cutaneous Leishmaniasis During TreatmentNCT07934446 · Not reported · University of Brasilia · starts Jan 8, 2025
- Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With LeishmaniasisNCT07783243 · Not reported · Institute of Tropical Medicine, Belgium · starts May 26, 2026
- LEISH-PED: Study on Leishmaniasis in ChildrenNCT07504757 · Not reported · Meyer Children's Hospital IRCCS · starts Jan 30, 2025
- Recurrent Visceral Leishmaniasis in HIV Co-InfectionNCT07487350 · Not reported · Institute of Tropical Medicine, Belgium · starts Oct 21, 2025
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveNCT07358910 · Not reported · Institut Pasteur du Cambodge · starts Dec 18, 2025
- Arnica Tincture Fot the Treatment of Cutaneous Leishmaniasis II.NCT06822478 · Phase 3 · Universidad de Antioquia · starts Mar 11, 2026
- Intralesional Injection of Metronidazole for the Management of Cutaneous LeishmaniasisNCT06798415 · Phase 2 · Hayder Adnan Fawzi · starts Feb 10, 2025
- Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium StibogluconateNCT06798402 · Phase 2 · Al-Mustafa University College · starts Feb 7, 2025
- Intralesional Injection of Levofloxacin for the Management of Cutaneous LeishmaniasisNCT06797544 · Phase 2 · Hayder Adnan Fawzi · starts Feb 9, 2025
Approved 8
- Miltefosine
- Stibogluconic acid
- PentamidineDNA inhibitor
- Acetarsone
- NitrofurazoneDNA inhibitor
- Benznidazole
- NifurtimoxDNA inhibitor
- FexinidazoleCytotoxic
Phase 3 8
- Amphotericin bErgosterol sequestering agent
- Meglumine antimonate
- ParomomycinBacterial 70S ribosome inhibitor
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- VoriconazoleCytochrome P450 51 inhibitor
- EflornithineOrnithine decarboxylase inhibitor
- SuraminAcidic fibroblast growth factor inhibitor
- Melarsoprol
Phase 2 5
- GentamicinBacterial 70S ribosome inhibitor
- AllopurinolXanthine dehydrogenase inhibitor
- PentoxifyllineAdenosine A2 receptor antagonist
- Sitamaquine
- 18-methoxycoronaridine
Phase 1 or earlier 6
- LEISH-F3
- SCH-708980Interleukin-10 inhibitor
- GSK-3494245
- Oleylphosphocholine
- GSK-3186899
- IvermectinGlutamate-gated chloride channel modulator
How its trials ended
193 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 61 whose ending is known, 48% met their primary endpoint, 11% missed it and 41% stopped early.
- Completed, result not reported9047%
- Met its primary endpoint2915%
- Ongoing2714%
- Status unknown158%
- Stopped: other or unclear105%
- Missed its primary endpoint74%
- Stopped: lack of efficacy74%
- Stopped: enrollment or feasibility63%
- Stopped: safety11%
- Stopped: sponsor or business decision11%
| Mar 19, 2014 | ImpavidoTreatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania… | Knight Therapeutics (USA) | Approved |
| Aug 11, 1997 | AmBisomeTreatment of visceral leishmaniasis. | Fujisawa USA, Inc. | Approved |
| Mar 20, 2025 | Parasite-selective proteasome inhibitor with potent…Treatment of leishmaniasis | Novartis Pharmaceuticals Corporation | Designated |
| Jan 23, 2024 | Imiquimod-Ferulic AcidTreatment of Cutaneous Leishmaniasis | Celista Pharmaceuticals LLC | Designated |
| Jul 19, 2021 | (2S)-2-[(2S)-4-cyclohexyl-2-{[(2S)-1-(4-fluorobenzoyl)pyrrol…Treatment of cutaneous leishmaniasis (Old World and New World) | Bacoba AG | Designated |
| Feb 11, 2015 | ParomomycinTreatment of cutaneous leishmaniasis (Old World and New World) | Appili Therapeutics Inc. | Designated |
| Jan 10, 2014 | Enchochleate amphotericin BTreatment of visceral leishmaniasis | Matinas BioPharma Nanotechnologies, Inc | Designated |
| Oct 25, 2013 | OleylphosphocholineTreatment of leishmaniasis | Oblita Therapeutics bvba | Designated |
| Jul 6, 2011 | CorifunginTreatment of visceral leishmaniasis | Sandler Center for Drug Discovery | Designated |
| Sep 15, 2010 | Amphotericin BTreatment of visceral leishmaniasis. | iCo Therapeutics Inc. | Designated |
| Jan 18, 2008 | Paromomycin sulfate/gentamicin sulfateTreatment of all uncomplicated cutaneous leishmaniasis (both New World and Old World) | Appili Therapeutics Inc. | Designated |
| Jun 16, 2006 | Sodium stibogluconateTreatment of cutaneous leishmaniasis | VioQuest Pharmaceuticals, Inc. | Designated |
| Mar 29, 2005 | AminosidineTreatment of visceral leishmaniasis | The Institute for One World Health | Designated |
| Sep 9, 1994 | AminosidineTreatment of visceral leishmaniasis (kala-azar). | Kanyok, Thomas P. Pharm.D. | Designated |
| Dec 4, 1985 | Allopurinol riboside1. Treatment of Chagas' disease 2. Treatment of cutaneous and visceral leishmaniasis | Burroughs Wellcome Company | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA